Ira M Jacobson

Summary

Affiliation: Cornell University
Country: USA

Publications

  1. ncbi request reprint Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial
    Ira M Jacobson
    Weill Cornell Medical College, New York, NY, USA Electronic address
    Lancet 384:403-13. 2014
  2. doi request reprint Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options
    Ira M Jacobson
    Weill Cornell Medical College, New York, NY 10021, USA
    N Engl J Med 368:1867-77. 2013
  3. doi request reprint Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin
    Ira M Jacobson
    Center for Study of Hepatitis C, Weill Cornell Medical College, New York, NY, USA
    Hepatology 56:567-75. 2012
  4. doi request reprint Standardization of terminology of virological response in the treatment of chronic hepatitis C: panel recommendations
    I M Jacobson
    Division of Gastroenterology and Hepatology, Center for the Study of Hepatitis C, Weill Cornell Medical College, New York, NY 10021, USA
    J Viral Hepat 19:236-43. 2012
  5. ncbi request reprint Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial
    Ira M Jacobson
    Weill Medical College of Cornell University, Center for the Study of Hepatitis C, New York Presbyterian Hospital, New York, NY 10021, USA
    Hepatology 46:971-81. 2007
  6. ncbi request reprint Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1
    Ira M Jacobson
    Weill Medical College of Cornell University, Center for the Study of Hepatitis C, New York Presbyterian Hospital, New York, NY 10021, USA
    Hepatology 46:982-90. 2007
  7. doi request reprint Telaprevir for previously untreated chronic hepatitis C virus infection
    Ira M Jacobson
    Weill Cornell Medical College and Center for the Study of Hepatitis C, New York, NY 10021, USA
    N Engl J Med 364:2405-16. 2011
  8. doi request reprint Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection
    Ira M Jacobson
    Division of Gastroenterology and Hepatology and Center for Study of Hepatitis C, Joan and Sanford I Weill Medical College of Cornell University, New York, New York 10021, USA
    Clin Gastroenterol Hepatol 8:924-33; quiz e117. 2010
  9. doi request reprint Manifestations of chronic hepatitis C virus infection beyond the liver
    Ira M Jacobson
    Center for the Study of Hepatitis C, Joan and Sanford I Weill Medical College of Cornell University, New York, New York 10021, USA
    Clin Gastroenterol Hepatol 8:1017-29. 2010
  10. ncbi request reprint Treatment options for patients with chronic hepatitis C not responding to initial antiviral therapy
    Ira M Jacobson
    Division of Gastroenterology and Hepatology, Center for the Study of Hepatitis C, Weill Cornell Medical College, New York, New York 10021, USA
    Clin Gastroenterol Hepatol 7:921-30. 2009

Detail Information

Publications62

  1. ncbi request reprint Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial
    Ira M Jacobson
    Weill Cornell Medical College, New York, NY, USA Electronic address
    Lancet 384:403-13. 2014
    ..The efficacy and safety of the combination of simeprevir, a one pill, once-daily, oral HCV NS3/4A protease inhibitor, plus peginterferon alfa 2a plus ribavirin were assessed in treatment-naive patients with HCV genotype 1 infection...
  2. doi request reprint Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options
    Ira M Jacobson
    Weill Cornell Medical College, New York, NY 10021, USA
    N Engl J Med 368:1867-77. 2013
    ..In phase 2 trials, regimens including the oral nucleotide polymerase inhibitor sofosbuvir have shown efficacy in patients with HCV genotype 2 or 3 infection...
  3. doi request reprint Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin
    Ira M Jacobson
    Center for Study of Hepatitis C, Weill Cornell Medical College, New York, NY, USA
    Hepatology 56:567-75. 2012
    ....
  4. doi request reprint Standardization of terminology of virological response in the treatment of chronic hepatitis C: panel recommendations
    I M Jacobson
    Division of Gastroenterology and Hepatology, Center for the Study of Hepatitis C, Weill Cornell Medical College, New York, NY 10021, USA
    J Viral Hepat 19:236-43. 2012
    ..Adoption of these terms would improve communication among investigators, enhance comparability among clinical trials, facilitate development of therapeutic guidelines and provide a standardized terminology for use in clinical practice...
  5. ncbi request reprint Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial
    Ira M Jacobson
    Weill Medical College of Cornell University, Center for the Study of Hepatitis C, New York Presbyterian Hospital, New York, NY 10021, USA
    Hepatology 46:971-81. 2007
    ..8% and 59.5%, respectively) regardless of treatment duration. Besides greater hemoglobin reductions with weight-based RBV, safety profiles were similar across RBV dosing groups, including the 1400-mg/day group...
  6. ncbi request reprint Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1
    Ira M Jacobson
    Weill Medical College of Cornell University, Center for the Study of Hepatitis C, New York Presbyterian Hospital, New York, NY 10021, USA
    Hepatology 46:982-90. 2007
    ..SVR rates were higher (21% versus 10%; P = 0.0006) and relapse rates were lower (22% versus 30%) in the weight-based-dose group than in the flat-dose group. Safety and rates of drug discontinuation were similar between the 2 groups...
  7. doi request reprint Telaprevir for previously untreated chronic hepatitis C virus infection
    Ira M Jacobson
    Weill Cornell Medical College and Center for the Study of Hepatitis C, New York, NY 10021, USA
    N Engl J Med 364:2405-16. 2011
    ....
  8. doi request reprint Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection
    Ira M Jacobson
    Division of Gastroenterology and Hepatology and Center for Study of Hepatitis C, Joan and Sanford I Weill Medical College of Cornell University, New York, New York 10021, USA
    Clin Gastroenterol Hepatol 8:924-33; quiz e117. 2010
    ..It is important to recognize the impact of HCV on liver disease progression and apply new therapeutic strategies...
  9. doi request reprint Manifestations of chronic hepatitis C virus infection beyond the liver
    Ira M Jacobson
    Center for the Study of Hepatitis C, Joan and Sanford I Weill Medical College of Cornell University, New York, New York 10021, USA
    Clin Gastroenterol Hepatol 8:1017-29. 2010
    ..Clinicians who treat patients with HCV infections should be aware of potential extrahepatic manifestations and how these can impact and alter management of their patients...
  10. ncbi request reprint Treatment options for patients with chronic hepatitis C not responding to initial antiviral therapy
    Ira M Jacobson
    Division of Gastroenterology and Hepatology, Center for the Study of Hepatitis C, Weill Cornell Medical College, New York, New York 10021, USA
    Clin Gastroenterol Hepatol 7:921-30. 2009
    ..Novel approaches, including combinations of direct antiviral agents, are needed to achieve major improvements in the treatment of nonresponders...
  11. ncbi request reprint A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C
    Ira M Jacobson
    Center for the Study of Hepatitis C and Division of Gastroenterology and Hepatology, Weill Medical College of Cornell University, New York, New York 10021, USA
    Am J Gastroenterol 100:2453-62. 2005
    ....
  12. doi request reprint IL28B polymorphism, pretreatment CXCL10, and HCV RNA levels predict treatment response in racially diverse HIV/HCV coinfected and HCV monoinfected patients
    Marija Zeremski
    Center for the Study of Hepatitis C and Division of Gastroenterology and Hepatology, Weill Cornell Medical College, New York, NY 10065, USA
    J Acquir Immune Defic Syndr 63:9-16. 2013
    ..We sought to develop a score to predict sustained virological response (SVR) in racially diverse HIV/hepatitis C virus (HCV)-coinfected and HCV-monoinfected pegylated interferon/ribavirin-treated patients...
  13. ncbi request reprint HIV/hepatitis C virus-coinfected patients with normal alanine aminotransferase levels
    Stevan A Gonzalez
    Center for the Study of Hepatitis C and Division of Gastroenterology and Hepatology, Department of Medicine, Weill Medical College of Columbia University, 525 East 68th Street, New York, NY 10021, USA
    J Acquir Immune Defic Syndr 41:582-9. 2006
    ..The significance of normal alanine aminotransferase (ALT) levels in patients with HIV/hepatitis C virus (HCV) coinfection is not well understood...
  14. ncbi request reprint A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update
    Emmet B Keeffe
    Division of Gastroenterology and Hepatology, Stanford University Medical Center, Stanford, California 94304 1509, USA
    Clin Gastroenterol Hepatol 6:1315-41; quiz 1286. 2008
    ..Issues for consideration for therapy include efficacy, safety, rate of resistance, method of administration, and cost...
  15. ncbi request reprint Interferon alfa-2b [correction of alpha-2b]and ribavirin for patients with chronic hepatitis C and normal ALT
    Ira M Jacobson
    Department of Gastroenterology and Hepatology, Weill Medical School of Cornell University, 450 East 69th Street, New York, NY 10021, USA
    Am J Gastroenterol 99:1700-5. 2004
    ..We sought to evaluate the efficacy of two doses of interferon alfa-2b (IFN) with ribavirin (RBV) in patients with normal ALT [correction]...
  16. doi request reprint Optimal treatment with telaprevir for chronic HCV infection
    Arun B Jesudian
    Division of Gastroenterology and Hepatology, Center for Study of Hepatitis C, NewYork Presbyterian Hospital Weill Cornell Medical College, New York, NY, USA
    Liver Int 33:3-13. 2013
    ..The most commonly observed side effects of telaprevir therapy are anaemia to a greater degree than that observed with PEG-IFN/ribavirin alone; eczematous rash, which can be severe in a minority of patients; and anorectal discomfort...
  17. ncbi request reprint Prognostic significance of hepatitis C virus RNA detection by transcription-mediated amplification with negative polymerase chain reaction during therapy with peginterferon alpha and ribavirin
    Jaydeep S Kadam
    Division of Gastroenterology and Hepatology and Center for the Study of Hepatitis C, Weill Medical College of Cornell University, New York, New York, USA
    Dig Dis Sci 52:2525-30. 2007
    ..03). Breakthrough occurred more frequently in discordant patients (24% vs. 3%; P=0.02). A positive TMA on two or more occasions in patients who have become PCR-negative on therapy indicates a high likelihood of treatment failure...
  18. ncbi request reprint Intrahepatic CD4+ cell depletion in hepatitis C virus/HIV-coinfected patients
    P Wilfredo Canchis
    Center for the Study of Hepatitis C, Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA
    J Acquir Immune Defic Syndr 37:1125-31. 2004
    ..09 cell/HPF) and monoinfected patients (0.45 +/- 0.08 cell/HPF). In conclusion, HIV coinfection is associated with fewer portal CD4 cells and increased lobular lymphocyte apoptosis that may impact on the natural history of HCV infection...
  19. pmc Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C
    David Butera
    Center for the Study of Hepatitis C, Laboratory of Virology and Infectious Disease, The Rockefeller University, Box 64, 1230 York Ave, New York, NY 10021, USA
    Blood 106:1175-82. 2005
    ..This observation has implications for understanding the pathogenesis of HCV infection...
  20. pmc Randomized trial comparing dose reduction and growth factor supplementation for management of hematological side effects in HIV/hepatitis C virus patients receiving pegylated-interferon and ribavirin
    Andrew H Talal
    Center for the Study of Hepatitis C, Division of Gastroenterology and Hepatology, Department of Medicine, Weill Cornell Medical College, New York, NY 10065, USA
    J Acquir Immune Defic Syndr 58:261-8. 2011
    ..Our objective was to compare the effectiveness of intervening with hematologic growth factors versus dose reductions of standard HCV therapy for the management of treatment-induced hematologic disorders...
  21. ncbi request reprint The role of hematopoietic growth factors in special populations with chronic hepatitis C: patients with HIV coinfection, end-stage renal disease, or liver transplantation
    Stevan A Gonzalez
    Center for the Study of Hepatitis C and the Division of Gastroenterology and Hepatology, Weill Medical College of Cornell University, New York, NY 10021, USA
    Cleve Clin J Med 71:S22-6. 2004
    ..This article reviews the rationale, current evidence, and future prospects for the adjunctive use of growth factors in these special populations with hepatitis C...
  22. ncbi request reprint Impact of Hispanic or Asian ethnicity on the treatment outcomes of chronic hepatitis C: results from the WIN-R trial
    Ke Qin Hu
    Division of Gastroenterology and Hepatology, University of California Irvine, Orange, CA 92868, USA
    J Clin Gastroenterol 45:720-6. 2011
    ..The aim of this subanalysis of the Weight-based Dosing of PegINterferon α-2b and Ribavirin (WIN-R) study was to assess the impact of Asian (n=118), Hispanic (n=289), and white (n=3919) ethnicity on CHC treatment outcomes...
  23. ncbi request reprint Therapeutic options for chronic hepatitis B: considerations and controversies
    Ira M Jacobson
    Division of Gastroenterology and Hepatology, Department of Medicine, Weill Medical College of Cornell University, 525 East 68th Street, New York, NY 10021, USA
    Am J Gastroenterol 101:S13-8. 2006
    ..The emergence of resistance to adefovir is delayed and infrequent, hence adefovir may be preferred in patients requiring long-term therapy...
  24. doi request reprint Peripheral CXCR3-associated chemokines as biomarkers of fibrosis in chronic hepatitis C virus infection
    Marija Zeremski
    Division of Gastroenterology and Hepatology and Center for the Study of Hepatitis C, Weill Cornell Medical College, New York, USA
    J Infect Dis 200:1774-80. 2009
    ..We evaluated the potential of peripheral chemokine levels to discriminate among patients with chronic HCV infection who had different stages of fibrosis...
  25. ncbi request reprint A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update
    Emmet B Keeffe
    Division of Gastroenterology and Hepatology, Stanford University Medical Center, CA 94304, USA
    Clin Gastroenterol Hepatol 4:936-62. 2006
    ..Issues for consideration include efficacy, safety, incidence of resistance, method of administration, and cost...
  26. pmc Clonal expansion of immunoglobulin M+CD27+ B cells in HCV-associated mixed cryoglobulinemia
    Edgar D Charles
    Center for the Study of Hepatitis C, Laboratory of Virology and Infectious Disease, Rockefeller University, New York, NY 10021, USA
    Blood 111:1344-56. 2008
    ..This study was registered at www.clinicaltrials.gov as NCT00219999...
  27. doi request reprint Telaprevir for chronic hepatitis C virus infection
    Arun B Jesudian
    Division of Gastroenterology and Hepatology, New York Presbyterian Hospital Weill Cornell Medical College, New York, USA
    Clin Liver Dis 17:47-62. 2013
    ..The most commonly observed side effects of telaprevir therapy are anemia to a greater degree than that observed with Peg-IFN/ribavirin alone; eczematous rash, which can be severe in a minority of patients; and anorectal discomfort...
  28. pmc Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset
    Edgar D Charles
    Center for the Study of Hepatitis C, Laboratory of Virology and Infectious Disease, Rockefeller University, 1230 York Avenue, New York, NY 10065, USA
    Blood 117:5425-37. 2011
    ..Down-regulation of multiple activation pathways may represent a homeostatic mechanism attenuating otherwise uncontrolled stimulation of circulating HCV-containing immune complexes...
  29. ncbi request reprint Treatment of relapsers after combination therapy for chronic hepatitis C
    Furqaan Ahmed
    Division of Hepatology and Gastroenterology, Weill Medical College of Cornell University, 450 East 69th Street, New York, NY 10021, USA
    Gastroenterol Clin North Am 33:513-26, viii. 2004
    ..Predictors of a favorable response to therapy in naïve patients appear to also predict response to therapy in patients who have relapsed previously...
  30. doi request reprint The first wave: HCV NS3 protease inhibitors telaprevir and boceprevir
    Kristen M Marks
    Division of Infectious Diseases, Weill Cornell Medical College, New York, NY, USA
    Antivir Ther 17:1119-31. 2012
    ..This review describes the clinical data supporting the approval and use of telaprevir and boceprevir, the algorithm for the use of these drugs, their adverse effects, as well as their important drug-drug interactions...
  31. pmc Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C
    Marija Zeremski
    Department of Medicine, Division of Gastroenterology and Hepatology, The Center for the Study of Hepatitis C, Weill Cornell Medical College, New York, NY 10065, USA
    Hepatology 48:1440-50. 2008
    ..Most intrahepatic lymphocytes express the CXCR3 receptor, and the number of CXCR3(+) lymphocytes was increased in patients with advanced necroinflammation...
  32. pmc Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis
    Rositsa B Dimova
    Weill Cornell Medical College, New York, NY 10065, USA
    Clin Infect Dis 56:806-16. 2013
    ..We assessed the effects of different treatment approaches and services to promote HCV care among DUs as well as demographic and viral characteristics...
  33. doi request reprint Recent successes and noteworthy future prospects in the treatment of chronic hepatitis C
    Alyson N Fox
    Division of Gastroenterology and Hepatology, Department of Medicine, Weill Cornell Medical College, 1305 York Avenue, New York, NY 10021, USA
    Clin Infect Dis 55:S16-24. 2012
    ..Recent proof of concept studies demonstrating the capacity to eradicate HCV without interferon signal the potential for yet another quantum leap in the field...
  34. ncbi request reprint Managing patients with hepatitis‑B-related or hepatitis‑C-related decompensated cirrhosis
    Scott A Fink
    New York Presbyterian Hospital Columbia University Medical Center, Center for Liver Disease and Transplantation, 622 West 168th Street, New York, NY 10032, USA
    Nat Rev Gastroenterol Hepatol 8:285-95. 2011
    ..This treatment is associated with improvement in decompensation in some patients. Hepatocellular carcinoma remains a significant risk in all patients with cirrhosis, and control of or eradication of HBV or HCV does not remove this risk...
  35. ncbi request reprint Normal functional capacity in circulating myeloid and plasmacytoid dendritic cells in patients with chronic hepatitis C
    Randy S Longman
    The Rockefeller University, The Cornell Rockefeller Sloan Kettering Tri Institutional MD PhD Program, New York, New York, USA
    J Infect Dis 192:497-503. 2005
    ..These results are encouraging for DC-based HCV immunotherapy trials...
  36. doi request reprint Emerging therapeutic targets for hepatitis C virus infection
    Arun B Jesudian
    Division of Gastroenterology and Hepatology, Center for the Study of Hepatitis C, New York Presbyterian Hospital, Weill Cornell Medical College, New York, USA
    Clin Gastroenterol Hepatol 11:612-9.e1. 2013
    ....
  37. ncbi request reprint Role of the nurse practitioner in the management of patients with chronic hepatitis C
    Mary Olson
    Weill Medical College of Cornell University, New York, New York, USA
    J Am Acad Nurse Pract 23:410-20. 2011
    ..To inform nurse practitioners (NPs) of the vital role they play in recognizing patients who may have hepatitis C...
  38. ncbi request reprint Hepatocyte proliferation in chronic hepatitis C: correlation with degree of liver disease and serum alpha-fetoprotein
    P Wilfredo Canchis
    Center for the Study of Hepatitis C, Weill Medical College of Cornell University, New York, NY 10021, USA
    Liver Int 24:198-203. 2004
    ..The relationships between HP and necroinflammation, fibrosis, and serum alpha-fetoprotein (AFP) levels in chronic hepatitis C virus (HCV) infection, however, are not well understood...
  39. doi request reprint Resistance-associated variants in chronic hepatitis C patients treated with protease inhibitors
    Maya Gambarin-Gelwan
    Division of Gastroenterology and Hepatology, Center for the Study of Hepatitis C, Weill Cornell Medical College, New York, NY 10021, USA
    Curr Gastroenterol Rep 14:47-54. 2012
    ..We will also explore the significance of resistant variants present at the baseline, as well as the fate of the resistant variants and the ways to minimize the development of resistance to protease inhibitors...
  40. doi request reprint Quality-of-life tradeoffs for hepatitis C treatment: do patients and providers agree?
    Bruce R Schackman
    Department of Public Health, Weill Medical College of Cornell University, New York, NY 10021, USA
    Med Decis Making 28:233-42. 2008
    ..Subjects completed rating scale and standard gamble evaluations of current health and hypothetical descriptions of HCV symptoms and treatment side effects on a scale from 0 (death or worse than death) to 1 (best possible health)...
  41. ncbi request reprint Telaprevir: hope on the horizon, getting closer
    Ilan S Weisberg
    Division of Gastroenterology and Hepatology, Department of Medicine, Center for the Study of Hepatitis C, Weill Cornell Medical College, New York Presbyterian Hospital, NY 10021, USA
    Clin Liver Dis 13:441-52. 2009
    ..In this report, the current experience using telaprevir to treat chronic HCV infection as monotherapy and in combination with other agents is reviewed...
  42. ncbi request reprint How to use statins in patients with chronic liver disease
    Mark W Russo
    Center for the Study of Hepatitis C, Division of Gastroenterology and Hepatology, Weill Cornell Medical College, New York, NY, USA
    Cleve Clin J Med 71:58-62. 2004
    ..However, patients with acute liver disease (acute viral hepatitis, alcoholic hepatitis) should not take statins until they have recovered...
  43. doi request reprint Cardiovascular diseases and the liver
    Ilan S Weisberg
    Division of Gastroenterology and Hepatology, Weill Cornell Medical Center, New York Presbyterian Hospital, 1305 York Avenue, 4th Floor, New York, NY 10021, USA
    Clin Liver Dis 15:1-20. 2011
    ....
  44. ncbi request reprint Slowing the progression of chronic hepatitis B. Early antiviral therapy can help minimize complications
    David B Purow
    Division of Gastroenterology and Hepatology, Joan and Sanford I Weill Medical College of Cornell University, 450 E 69th St, New York, NY 10021, USA
    Postgrad Med 114:65-8, 73-6. 2003
    ..In this article, the authors explore the modes of HBV transmission, describe the characteristics of chronic infection, and review the drugs available to treat it...
  45. ncbi request reprint New and experimental therapies for HCV
    Arema A Pereira
    Weill Cornell Medical College, Center for the Study of Hepatitis C, New York, NY 10021, USA
    Nat Rev Gastroenterol Hepatol 6:403-11. 2009
    ....
  46. ncbi request reprint Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C
    K Shiva Kumar
    Center for Liver Disease and Transplantation, New York Presbyterian Hospital, New York, USA
    Am J Gastroenterol 97:2432-40. 2002
    ..The aim of this study was to analyze the clinical presentation and outcomes of significant pulmonary toxicity associated with interferon and ribavirin...
  47. ncbi request reprint The role of the woodchuck model in the treatment of hepatitis B virus infection
    Ketan Kulkarni
    Division of Gastroenterology and Hepatology, Department of Medicine, Weill Medical College of Cornell University, 1305 York Avenue, 4th Floor, New York, NY 10021, USA
    Clin Liver Dis 11:707-25, vii. 2007
    ..Furthermore, we consider the implications of studies focusing on the natural history of WHV infection for the management of HBV and the capacity of treatment to prevent complications of chronic hepatitis B infection...
  48. ncbi request reprint Accumulation of B lymphocytes with a naive, resting phenotype in a subset of hepatitis C patients
    Jianhua Ni
    Center for the Study of Hepatitis C, Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10021, USA
    J Immunol 170:3429-39. 2003
    ..Instead, factors other than antigenic stimulation may promote the accumulation of peripheral blood B cells with a naive phenotype in a subset of HCV patients...
  49. ncbi request reprint Screening and diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis
    Arun B Jesudian
    Division of Gastroenterology and Hepatology, Weill Cornell Medical Center, New York, NY, USA
    Rev Gastroenterol Disord 9:E41-7. 2009
    ..Newer treatment options for early CCA such as resection and liver transplantation have shown promising results, making an effective screening regimen for the detection of CCA at a treatable stage in PSC patients a highly coveted goal...
  50. ncbi request reprint Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus
    John G McHutchison
    ALT Alliance for Liver Therapy Group, Division of Gastroenterology and Hepatology and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Hepatology 46:1341-9. 2007
    ..5-log(10) reduction. CPG 10101 was well tolerated, and adverse events were consistent with CPG 10101's mechanism of action...
  51. ncbi request reprint Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety
    Mark W Russo
    Division of Digestive Diseases and Nutrition, University of North Carolina, Chapel Hill, North Carolina 27599, USA
    Am J Gastroenterol 98:1610-5. 2003
    ..Effective treatment of chronic HCV is needed in this group of patients. We aimed to determine from the literature the efficacy and safety of interferon monotherapy in dialysis patients with chronic HCV...
  52. ncbi request reprint Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C
    Charles L Raison
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA
    Brain Behav Immun 19:23-7. 2005
    ....
  53. pmc Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction
    Charles L Raison
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA 30322, USA
    J Clin Psychiatry 66:41-8. 2005
    ..Newer, pegylated preparations of IFN-alpha have a longer half-life, require once-per-week dosing, and may be associated with reduced neuropsychiatric burden. Limited data exist on depression during pegylated IFN-alpha therapy...
  54. doi request reprint WIN-R revisited: Response to editorial
    Ira M Jacobson
    Hepatology 47:1427. 2008
  55. ncbi request reprint Clinical course of chronic hepatitis C in patients with very high serum alpha-fetoprotein levels and normal hepatic imaging
    Stevan A Gonzalez
    Am J Gastroenterol 100:977-8. 2005
  56. ncbi request reprint Combination therapy for chronic hepatitis B: ready for prime time?
    Ira M Jacobson
    J Hepatol 48:687-91. 2008
  57. ncbi request reprint Halting the natural history of hepatitis B viral infection: a paradigm shift
    Robert P Perrillo
    Hepatology Division, Baylor University Medical Center, 3500 Gaston Avenue, Dallas, TX 75246, USA
    Semin Liver Dis 27:3-8. 2007
    ..A satellite symposium conducted during the 57th Annual Meeting of the AASLD in Boston, Massachusetts, presented new findings relative to the course of HBV infection...
  58. ncbi request reprint A treatment algorithm for the management of chronic hepatitis B virus infection in the United States
    Emmet B Keeffe
    Stanford University Medical Center, 750 Welch Road, Suite 210, Palo Alto, California 94304 1509, USA
    Clin Gastroenterol Hepatol 2:87-106. 2004
    ....
  59. ncbi request reprint Presence of functional dendritic cells in patients chronically infected with hepatitis C virus
    Randy S Longman
    Institut Pasteur, 25, rue du Dr Roux, Paris, France 75724
    Blood 103:1026-9. 2004
    ..This finding is consistent with clinical and immunologic data that the deficit in the patient's immune repertoire is HCV-specific and suggests that refined models are required for understanding the role of DCs in HCV pathogenesis...
  60. ncbi request reprint Customizing the management of chronic hepatitis B virus infection
    Robert G Gish
    Division of Hepatology and Complex GI, Physicians Foundation, California Pacific Medical Center, 2340 Clay Street, San Francisco, CA 94115, USA
    Semin Liver Dis 27:9-17. 2007
    ..The presentation highlighted recent findings suggesting that early, profound, and sustained viral suppression improves the probability of sustained virologic response and reduces the likelihood of nucleos(t)ide resistance...
  61. ncbi request reprint Treating chronic hepatitis B infection in patients who are pregnant or are undergoing immunosuppressive chemotherapy
    Norah A Terrault
    Division of Gastroenterology, University of California San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143, USA
    Semin Liver Dis 27:18-24. 2007
    ....
  62. ncbi request reprint Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B
    Emmet B Keeffe
    Stanford University School of Medicine, Stanford, California 94304 1509, USA
    Clin Gastroenterol Hepatol 5:890-7. 2007
    ..Future studies of the use of the roadmap concept in improving outcomes of chronic hepatitis B are warranted...